Abstract: The present disclosure relates to a positive electrode active material for rechargeable lithium ion batteries and a method of preparing the positive electrode active material, in which a compound including sulfur is used as an additive in a wet treatment process to remove residual lithium impurities (LiOH, Li2CO3) present on a surface of the positive electrode active material, such that the residual lithium impurities are effectively removed without loss of capacity while a Li—S compound coating layer is formed on the surface thereof, thereby reducing resistance and leakage current.

Abstract: The present disclosure relates to a positive electrode active material for rechargeable lithium ion batteries and a method of preparing the positive electrode active material, in which a compound including sulfur is used as an additive in a wet treatment process to remove residual lithium impurities (LiOH, Li2CO3) present on a surface of the positive electrode active material, such that the residual lithium impurities are effectively removed without loss of capacity while a Li-S compound coating layer is formed on the surface thereof, thereby reducing resistance and leakage current.

Abstract: The present disclosure relates to a positive active material for a lithium rechargeable battery, a manufacturing method thereof, and a lithium rechargeable battery including the positive active material, and it provides a positive active material which is a lithium composite metal oxide including nickel, cobalt, and manganese, and either has orientation in a direction of with respect to an ND axis that is equal to or greater than 29% or has orientation in a direction of [120]+[210] with respect to an RD axis that is equal to or greater than 82% in the case of an EBSD analysis with a misorientation angle (?g) that is equal to or less than 30 degrees.

Abstract: An anti-c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject are provided.

Abstract: The present disclosure relates to a positive active material for a lithium rechargeable battery, a manufacturing method thereof, and a lithium rechargeable battery including the positive active material, and it provides a positive active material which is a lithium composite metal oxide including nickel, cobalt, and manganese, and either has orientation in a direction of [001] with respect to an ND axis that is equal to or greater than 29% or has orientation in a direction of [120]+[210] with respect to an RD axis that is equal to or greater than 82% in the case of an EBSD analysis with a misorientation angle (?g) that is equal to or less than 30 degrees.

Abstract: The present disclosure relates to a positive electrode active material for rechargeable lithium ion batteries and a method of preparing the positive electrode active material, in which a compound including sulfur is used as an additive in a wet treatment process to remove residual lithium impurities (LiOH, Li2CO3) present on a surface of the positive electrode active material, such that the residual lithium impurities are effectively removed without loss of capacity while a Li-S compound coating layer is formed on the surface thereof, thereby reducing resistance and leakage current.

Abstract: A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.

Abstract: A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided.

Abstract: An anti-c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject are provided.

Abstract: Disclosed herein are bio-markers for diagnosing diabetic retinopathy, a use of proteins, whose expression level down-regulated or up-regulated in the tears of a non-proliferative diabetic retinopathy (NPDR) patient, as bio-markers for diagnosing diabetic retinopathy, and a composition and kit for diagnosing diabetic retinopathy comprising antibodies against said proteins.

Abstract: Disclosed herein are bio-markers for diagnosing diabetic retinopathy, a use of proteins, whose expression level down-regulated or up-regulated in the tears of a non-proliferative diabetic retinopathy (NPDR) patient, as bio-markers for diagnosing diabetic retinopathy, and a composition and kit for diagnosing diabetic retinopathy comprising antibodies against said proteins.